Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
Schatz CA, Zitzmann-Kolbe S, Moen I, Klotz M, Nair S, Stargard S, Bjerke RM, Wickstrøm Biseth K, Feng YZ, Indrevoll B, Cruciani V, Karlsson J, Haendler B, Nielsen CH, Alfsen MZ, Hammer S, Hennekes H, Cuthbertson A, Hagemann UB, Larsen A.
Schatz CA, et al. Among authors: larsen a.
Clin Cancer Res. 2024 Apr 9. doi: 10.1158/1078-0432.CCR-23-3746. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 38593212